biosimilars

Views & Analysis

2021 market access prospects for Spain

2021 will be the year when big market access changes – including the far wider use of health economic evaluation – are implemented in Spain.

Views & Analysis

Nine for 2021: Addressing the pandemic legacy

In this second 'Nine for 2021' article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact pharma in 2021: t

News

Novartis set to overcome $14 billion patent cliff say analys...

Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said.

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA begins review of Samsung Bioepis/Biogen's Lucentis biosi...

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen

News

COVID-19 tests prop up Roche as US biosimilars bite in Q3

Roche’s pharmaceutical revenues have been hit by falling sales in its pharma division in Q3 but a spike in demand for COVID-19 tests spared the Swiss company's blushes.

News

Amgen's cancer biosimilars stay on US market as court battle...

Amgen has scored yet another home run in the US courts, this time seeing off a legal challenge from Genentech, which was trying to block it from launching two cut-price cancer biosimilars.

2021 market access prospects for Spain

Nine for 2021: Addressing the pandemic legacy

Novartis set to overcome $14 billion patent cliff say analys...

FDA begins review of Samsung Bioepis/Biogen's Lucentis biosi...

COVID-19 tests prop up Roche as US biosimilars bite in Q3

Amgen's cancer biosimilars stay on US market as court battle...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

biosimilars

Editor's Picks